Navigation Links
Omthera Pharmaceuticals Raises $33.9 Million in Series B Funding Led by New Enterprise Associates
Date:3/14/2011

BEDMINSTER, N.J., March 14, 2011 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms.  Existing investor, Sofinnova Partners, also participated in the financing. The capital raised will be used to fund the Phase 3 clinical development of Omthera's novel Omega-3 fatty acid compound, Epanova™, and for general corporate purposes.  With this latest round, Omthera has raised approximately $40.4 million in venture capital since commencement of operations in 2009.

In a separate press release issued today, Omthera announced that the Company has initiated its pivotal Phase III EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial for Epanova, for the treatment of patients with very high triglycerides (greater than or equal to 500 mg/dL).  In January 2011, the Company announced data from its ECLIPSE (Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation) trial, designed to evaluate the bioavailability of Epanova in comparison to Lovaza®, the leading prescription Omega-3.  Data from the trial showed that the bioavailability of Epanova was dramatically superior to Lovaza.

"Omthera continues to generate very positive data indicating that Epanova has the potential to become the best-in-class therapy in the nearly $2 billion worldwide Rx Omega-3 market and an important treatment for the millions of patients suffering from high triglycerides," stated Jerry Wisler, President, Chief Executive Officer and co-founder of Omthera. "As such, we are delighted to gain the support of a venture capital firm of the stature of NEA to lead this substantial new funding."  

David M. Mott, f
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omthera Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
2. Omthera Pharmaceuticals, Inc. to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  Today DePuy Synthes Companies of Johnson ... systems featuring its proprietary variable angle locking technology. ... to match patient anatomy and fracture pattern and ... systems are being introduced in conjunction with the ... the International Federation of Foot & Ankle Societies ...
(Date:9/19/2014)... VIEW, Calif. , Sept. 19, 2014 Today, ... in capital from Xiaomi Ventures, Ltd. for its first ... used to continue expanding iHealth,s global reach, accelerate growth ... resources.  As part of the investment, Xiaomi Ventures will ... the areas of cloud infrastructure and ecommerce. ...
(Date:9/19/2014)...  The board of directors of AbbVie Inc. (NYSE: ... of $0.42 per share.  The cash ... record at the close of business on Oct. 15, ... research-based biopharmaceutical company formed in 2013 following separation from ... dedicated people and unique approach to innovation to develop ...
Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3iHealth Raises $25 Million to Fuel Growth and Global Market Share 2
... Cargill today announced encouraging preliminary results from its ... head of beef cattle.  Initial results are based upon ... company,s Fort Morgan, Colo., beef processing facility where vaccinated ... Addressing the food and feed safety ...
... Nov. 15, 2010 Breathe Technologies, manufacturer of devices ... has appointed Lawrence A. Mastrovich as the new President ... us a phenomenal wealth of experience and strategic guidance," ... visible and instrumental role in building value within the ...
Cached Medicine Technology:Cargill Encouraged by Preliminary Results From Beef Cattle Vaccine Trial 2Cargill Encouraged by Preliminary Results From Beef Cattle Vaccine Trial 3Breathe Technologies Appoints New CEO 2
(Date:9/21/2014)... of cancer patients who smoke, those using e-cigarettes (in ... equally or less likely to have quit smoking traditional ... , a peer-reviewed journal of the American Cancer Society, ... e-cigarettes for helping cancer patients give up smoking. , ... patients who smoke should be advised to quit. But ...
(Date:9/21/2014)... Texas (PRWEB) September 22, 2014 ... originally launched in 1997, and is used prophylactically ... and adults. Its active ingredient, budesonide, is an ... corticosteroid receptor. AstraZeneca’s Pulmicort franchise includes the Pulmicort ... than six years of age, Pulmicort Respules for ...
(Date:9/21/2014)... More than a quarter of house fires are started ... two ways. The first type of dryer fire occurs when ... of dryer fire occurs when lint builds up in the dryer ... to malfunctioning electrical systems so if it doesn’t appear to be ... are some ways that you can prevent dryer fires. , Clean ...
(Date:9/21/2014)... 21, 2014 Burnaby Physiotherapists at Absolute ... clients in order to help them with preventative care. ... the clinic that will help clients understand their problem ... take active participation in the healing process. With higher ... will be able to facilitate the therapy that is ...
(Date:9/21/2014)... 21, 2014 Waldorf Risk Solutions, ... Portal designed for Diocesan risks. The portal features ... support effective risk management and loss control client ... coinciding with Waldorf’s exhibition at the Diocesan Fiscal ... applications were developed in collaboration with three Risk ...
Breaking Medicine News(10 mins):Health News:E-cigarettes unhelpful in smoking cessation among cancer patients 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Restoration Local Offers Tips to Avoid Dryer Fires 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 3Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:Waldorf Risk Solutions Releases New Risk Management Portal 2
... , , CHICAGO, July 14 ... people of Chicago, SAVE THE PATIENT, a not-for-profit patient-focused organization, ... Chicago Access Network Television (CAN-TV) airing Monday, July 20, 2009 ... , Monday,s program will feature a ...
... , , , ... leading developer of video analytics-enabled products, announced today that ... Cernium,s server-based enterprise video analytics software solution. Perceptrak will ... the Baltimore, Maryland medical center campus. , ...
... , , OAKLAND, Calif., July 14 ... Health Manager, Kaiser Permanente,s personal health record, are overwhelmingly satisfied with ... from the recent Kaiser Permanente survey examining Web site usage and ... Congress, 5th Annual Leadership Summit on Medicare in Washington, D.C. , ...
... prevent injuries, experts say , TUESDAY, July 14 (HealthDay News) ... and your mental health. , But running can be tough ... shin splints, stress fractures, pulled muscles, ankle sprains, plantar fasciitis ... back. , To prevent injuries, make sure you take precautions, ...
... better screening: study , TUESDAY, July 14 (HealthDay News) ... cancers noted in the United States since 1980, and scientists ... A new study finds that thyroid tumors of all sizes ... more aggressive screening would be expected to detect. , ...
... , , SAN DIEGO, ... today announced that OraVerse(R), the company,s premier dental pharmaceutical product, has ... of its Top 100 Products for 2009. The full results ... , , OraVerse is the first ...
Cached Medicine News:Health News:Women's Health - An Intimate Discussion 2Health News:Johns Hopkins Medical Institutions Deploys Perceptrak(R) by Cernium 2Health News:Kaiser Permanente Survey Shows Seniors Embrace Internet to Manage Their Health 2Health News:Kaiser Permanente Survey Shows Seniors Embrace Internet to Manage Their Health 3Health News:Get the Most Out of Your Run 2Health News:Get the Most Out of Your Run 3Health News:Increase in Thyroid Cancer Puzzles Experts 2Health News:OraVerse (R) Selected by Dentistry Today Magazine as One of the Top 100 Products of 2009 2Health News:OraVerse (R) Selected by Dentistry Today Magazine as One of the Top 100 Products of 2009 3
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
... that quantitatively measure two important cardiac risk ... serum or plasma homocysteine level is increasingly ... factor for cardiovascular disease. And numerous studies ... levels of Lp(a) with increased risk of ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
Anti-Skin Antibody (ASA) Test Kit: Pemphigus and Bullous Pemphigoid...
Medicine Products: